GPT Healthcare's Q3 FY26: Navigating Growth and Strategic Expansion in Eastern India

GPT Healthcare Limited, a prominent hospital chain in Eastern India, has released its financial results for the third quarter and nine months ended December 31, 2025 (Q3 & 9MFY26). The company reported a robust top-line performance, with revenue from operations reaching INR 350.5 crore for the nine-month period, marking a healthy 12.12% year-on-year growth. For the standalone Q3 FY26, revenue stood at INR 121.6 crore, a significant 16.81% increase compared to the same quarter last year. This growth was primarily driven by improved occupancies, a better case mix, and higher throughput across its network of hospitals. The Average Revenue Per Occupied Bed (ARPOB) also saw a commendable 6% year-on-year increase, reaching ₹38,797, reflecting strengthened clinical offerings and continued operational efficiencies.

Despite the strong revenue growth, the company experienced some pressure on its profitability margins. The EBITDA for the nine-month period was INR 65.1 crore, with an EBITDA margin of 18.58%, a decrease from 22.26% in 9MFY25. Similarly, Profit After Tax (PAT) for 9MFY26 stood at INR 27.6 crore, translating to a PAT margin of 7.89%, down from 11.85% in the previous fiscal. This margin contraction is largely attributable to the ramp-up phase of the newly commissioned Raipur facility, which incurred EBITDA losses during the period, as well as increased promotional expenses.

Operational Highlights and Strategic Initiatives

GPT Healthcare's operational strategy revolves around a proximity-based model, offering advanced medical care in densely populated residential areas. The company is actively pursuing a vision to expand to a 1,000-bed network by 2027, supported by integrated diagnostics and a strong regional brand. Several key initiatives are underway to achieve this goal and enhance operational performance across its existing facilities.

One of the significant developments is the progress of the 150-bed Jamshedpur tertiary care project. Following the signing of a Memorandum of Understanding (MOU), design, planning, and phasing activities are in full swing, with commissioning targeted by the end of FY27. This project, with an investment of INR 75 crore, is expected to significantly strengthen the company's presence in underserved regions and contribute meaningfully to future revenue growth and case mix.

In terms of clinical capability enhancement, the ILS-Dum Dum hospital commissioned Cardiothoracic and Vascular Surgery (CTVS) services, ensuring comprehensive cardiac care. This initiative has already shown positive traction, with approximately 15 successful surgeries performed in the past month. The Agartala Hospital, the only corporate tertiary care hospital in Tripura, launched comprehensive cancer care services, including PET scan and Linear Accelerator, making it the state's sole integrated oncology unit. This has led to a 10% increase in productivity in oncology services. The Howrah Hospital also commenced robot-assisted orthopedic surgeries, including robotic knee replacements, which is expected to boost ARPOB and reduce the average length of stay (ALOS).

Financial Summary (INR Crore)

Navigating Challenges and Future Outlook

The company acknowledged challenges such as the occupancy rate dip in ILS-Dum Dum, which management attributed to a restructuring exercise focused on reducing dependence on certain departments and activating newer, high-ARPOB, low-length-of-stay services. This strategic shift is already yielding results, with patient numbers remaining stable or growing despite the lower occupancy. For Agartala, the impact of reduced patient flow from Bangladesh was noted, and the company has proactively redirected its marketing and productivity efforts within Tripura and North Tripura.

GPT Healthcare's Raipur facility, which commenced operations in May 2025, is still in its ramp-up phase and recorded an EBITDA loss of INR 2.5 crore in Q3 FY26. However, management is confident that the facility is on track to achieve EBITDA breakeven within the next 6 to 8 months. The company's capital-efficient execution model, characterized by an industry-fastest break-even period of 8-10 months and a capex per bed of ₹7–8Mn, significantly below industry norms, underpins its expansion strategy. The company remains net-debt free, further strengthening its financial position for future growth.

Hospital-wise Performance (9M FY26)

GPT Healthcare is well-positioned to capitalize on emerging opportunities in the Indian healthcare industry, including medical tourism, policy-backed growth, and untapped rural demand. The company's focus on affordable care, coupled with continuous improvement in asset productivity and service quality, aligns with the growing demand for accessible healthcare, particularly in Eastern India. The strategic emphasis on expanding reach and strengthening clinical capabilities, supported by technological innovations, forms the core of its long-term growth trajectory.

Concluding Thoughts

GPT Healthcare Limited's Q3 and 9MFY26 results reflect a period of dynamic growth and strategic realignment. While the integration of new facilities like Raipur presents short-term margin pressures, the underlying operational improvements, targeted expansions, and focus on high-value clinical services demonstrate a clear path forward. The management's proactive approach to optimizing existing assets and disciplined capital allocation underscore its commitment to sustained value creation for investors in the evolving Indian healthcare landscape.